Myriad Genetics (MYGN) said Wednesday it expects Q4 adjusted earnings of $0.03 to $0.04 per diluted share.

Analysts surveyed by FactSet expect $0.03.

Revenue for the quarter ended Dec. 31 is expected to be in the range of $209 million to $211 million, up by about 6% to 7% from a year earlier.

Analysts polled by FactSet expect $212.9 million.

The company said it now expects 2024 adjusted EPS of $0.14 to $0.15, versus its prior guidance for $0.12 to $0.14, while revenue is now expected to be between $836 million and $838 million, compared with its guidance for $837 million to $843 million. Analysts polled by FactSet expect adjusted EPS of $0.13 on revenue of $840 million.

For 2025, the company said it expects adjusted EPS of $0.07 to $0.11 on revenue of $840 million to $860 million. Analysts surveyed by FactSet expect adjusted EPS of $0.15 on revenue of $879.5 million.

Myriad Genetics said it intends to release its actual Q4 and full-year 2024 results in February.